<DOC>
	<DOCNO>NCT00221702</DOCNO>
	<brief_summary>Melanoma tumor thickness &gt; = 1.5mm without clinically detectable node represent increase population relapse rate 50 % . Adjuvant therapy low dos IFN alpha provide benefit group . However , impact low dose IFN alpha sustain treatment period . A longer treatment may prolong benefit thus clear-cut impact disease-free overall survival . The tolerance impact quality life limit factor group patient whose individual course necessarily poor . PegIntron may well tolerate instant release interferon , thus make treatment acceptable term toxicity quality life . Thus treatment schedule PegIntron expect increase cost standard care significantly .</brief_summary>
	<brief_title>PegIntron Versus IntronA CMAJCC Stage II ( EADO 2001/CMII Trial )</brief_title>
	<detailed_description>Study design primary objective This European multicenter , open label , prospective randomize phase III trial evaluate efficacy long-term maintenance therapy two therapy option , IntronA 18 month versus PegIntron 36 month , administer adjuvant set local excision intermediate risk cutaneous melanoma . Eligibility criteria Intermediate risk melanoma define follow criterion : ( 1 ) tumor thickness &gt; = 1,5mm ( 2 ) absence regional nodal macrometastases , assess either clinical examination , sentinel lymph node biopsy ( SLNB ) elective node dissection ( ELND ) perform , absence macroscopic evidence disease . Patients evidence nodal micrometastasis SLNB ELND eligible . The choice perform sentinel node dissection leave decision center , condition concern consecutive patient surgical procedure complete randomization patient . The center inform respective national study center perform SLNB ELND also change surgical procedure . Study treatments - Arm A : PegIntron 100 mcg SC/week 36 month - Arm B : IntronA 3miu TIWW SC 18 month Endpoints The primary endpoint study time recurrence ( local recurrence , satellite transit metastasis , regional node metastasis distant metastasis ) death , whatever cause . The primary comparison two arm use 5-year disease-free survival time . Secondary endpoint time distant metastasis , overall survival , toxicity quality life . Therapy either PegIntron IntronA continue schedule unless evidence disease progression ( whether local distant recurrence ) , severe toxicity , subject request therapy discontinue . All patient follow disease-free-survival overall survival end trial . Sample size analysis The calculated sample size 1190 patient enrol 5 year period ; sample size inclusive expect lose follow 10 % course trial . The randomization procedure stratify accord center sentinel node biopsy . The primary analysis perform intent treat principle .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Histologically proven cutaneous melanoma Tumour thickness &gt; = 1.5 mm ( Breslow stag ) Absence clinically detectable regional node metastasis , evidence distant metastasis Informed consent form sign Any prior chemo , immuno , hormonal radiation therapy Macroscopic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Neoplasm metastasis</keyword>
	<keyword>Interferon alfa-2b</keyword>
	<keyword>Adjuvants</keyword>
	<keyword>Randomized clinical trial</keyword>
	<keyword>Disease-free survival time</keyword>
	<keyword>Safety</keyword>
	<keyword>Drug toxicity</keyword>
	<keyword>Quality life</keyword>
</DOC>